EP2818470A1 — Cocrystals of raltegravir potassium
Assigned to BASF SE · Expires 2014-12-31 · 11y expired
What this patent protects
Novel solid forms of Raltegravir potassium comprising the active ingredient N-[2-[(4Z)-4-[[(4-fluorophenyl)methylamino]-hydroxymethylidene]-1-methyl-5,6-dioxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide as potassium salt co-crystal with cyclamic acid, sacch…
USPTO Abstract
Novel solid forms of Raltegravir potassium comprising the active ingredient N-[2-[(4Z)-4-[[(4-fluorophenyl)methylamino]-hydroxymethylidene]-1-methyl-5,6-dioxopyrimidin-2-yl]propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide as potassium salt co-crystal with cyclamic acid, saccharin, stearic acid or succinic acid. The multi-component crystalline forms show improved properties such as dissolution kinetic and hydration stability.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.